Ligand id: 8254

Name: ozanezumab

No information available.
Summary of Clinical Use
Ozanezumab has reached Phase II clinical trial for ALS (see NCT01753076). Two Phase I trials of ozanezumab in MS have been terminated.
Mechanism Of Action and Pharmacodynamic Effects
NOGO-A is expressed in higher levels in the central nervous system of ALS patients, where the protein appears to inhibit neurite outgrowth. This inhibitory effect reduces the capacity of neurons to form junctions with muscles, promoting denervation which leads to muscle weakness [4]. Inhibiting this action of NOGO-A is predicted to abrogate the loss of connections between motor neurones and muscles. The role of aberrant axon guidance in ALS is reviewed in [5]..

Studies using murine monoclonal IN-1 [2] helped to confirm that anti-NOGO-A antibodies have neurite outgrowth potentiating activity [1,6], and that NOGO-A represents a viable and druggable target. Patent US8362208 covers GlaxoSmithKline's development of anti-NOGO-A antibodies [3], with clone H28L16 being a likely candidate for ozanezumab.